Literature DB >> 26433853

Diagnosis and Management of Cutaneous B-cell Lymphoma.

Lauren C Pinter-Brown1.   

Abstract

The diagnosis of primary cutaneous B-cell lymphoma (CBCL) requires that the search for a more widespread lymphoma has been negative. The clinical presentation, outlook, and treatment options of the common types of CBCLs, with emphasis on differences or similarities to their nodal counterparts, are discussed. Treatment may range from observation to topical therapies to systemic therapies, depending on the histology, degree and area of skin involvement, patient performance, and comorbidities. Rare lymphomas, such as intravascular large B-cell lymphoma and Epstein-Barr virus-positive cutaneous lymphoproliferations that are associated with immunodeficiency, are also briefly described.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous B-cell lymphoma; DLBCL, leg type; Marginal zone lymphoma; Primary cutaneous follicle center lymphoma; Primary cutaneous lymphoma

Mesh:

Year:  2015        PMID: 26433853     DOI: 10.1016/j.det.2015.05.003

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  3 in total

Review 1.  Primary Cutaneous B-Cell Lymphomas: An Update.

Authors:  Paola Vitiello; Antonello Sica; Andrea Ronchi; Stefano Caccavale; Renato Franco; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

Review 2.  Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas.

Authors:  Andrea Ronchi; Antonello Sica; Paola Vitiello; Renato Franco
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-03-08

3.  Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options.

Authors:  Changjun Chen; Meng Si; Xianlei Gao; Wenhan Wang; Songgang Wang; Xin Pan
Journal:  Postepy Dermatol Alergol       Date:  2021-08-16       Impact factor: 1.664

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.